Latest Conference Articles

April 9th 2020, 11:54pm

SGO Annual Meeting

David O’Malley, MD, discusses the rationale to evaluate the clinical benefit of rucaparib maintenance treatment following disease progression in a subgroup of patients with ovarian cancer whose disease is associated with a mutation in a non-BRCA homologous recombination gene in the phase III ARIEL3 trial in ovarian cancer.

April 9th 2020, 11:18pm

SGO Annual Meeting

Amanda Nickles Fader, MD, discusses findings from a randomized phase II trial examining the efficacy of adding trastuzumab to carboplatin/paclitaxel in patients with advanced or recurrent uterine serous carcinomas that overexpress HER2/neu.

April 8th 2020, 9:14pm

SGO Annual Meeting

The combination of olaparib and bevacizumab was found to improve progression-free survival outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the timing of surgery or residual disease status after surgery.

April 8th 2020, 6:40pm

SGO Annual Meeting

The combination of niraparib and bevacizumab as a frontline maintenance therapy was found to have impressive clinical activity in patients with advanced ovarian cancer who had a complete or partial response to frontline platinum-based chemotherapy plus bevacizumab.

April 7th 2020, 7:47pm

SGO Annual Meeting

Trametinib monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study.

April 6th 2020, 11:37pm

SGO Annual Meeting

Adding veliparib to frontline induction chemotherapy increased complete and CA-125 responses compared with chemotherapy alone in patients with high-grade serous ovarian cancer, according to an exploratory analysis of the phase III VELIA trial.

April 4th 2020, 1:37am

SGO Annual Meeting

Dana Chase, MD, discusses niraparib as frontline maintenance therapy in ovarian cancer.

April 3rd 2020, 10:57pm

SGO Annual Meeting

Rucaparib was associated with superior outcomes among women with ovarian cancer harboring a non-BRCA homologous recombination repair gene mutation compared with placebo, according to an analysis of specimens collected in the phase III ARIEL3 trial (NCT01968213).

April 3rd 2020, 1:59am

SGO Annual Meeting

The anti-DLL4/VEGF bispecific antibody navicixizumab showed promising clinical activity when used in combination with paclitaxel in heavily pretreated patients with platinum-resistant ovarian cancer.

April 3rd 2020, 12:38am

SGO Annual Meeting

Frontline maintenance treatment with Vigil immunotherapy demonstrated an improvement in relapse-free survival compared with placebo in patients with stage III/IV ovarian cancer, especially in those with BRCA1/2 wild-type disease.

April 2nd 2020, 10:50pm

SGO Annual Meeting

Elizabeth M. Swisher, MD, discusses how the phase III VELIA/GOG-3005 trial compares with other trials examining up-front maintenance therapy in ovarian cancer.

April 2nd 2020, 6:53pm

SGO Annual Meeting

Veliparib plus chemotherapy extended progression-free survival for BRCA wild-type patients with high-grade serous carcinoma.

March 21st 2020, 2:36am

School of Gastrointestinal Oncology

Manish A. Shah, MD, discusses the role of immunotherapy in gastroesophageal cancer.

March 21st 2020, 2:23am

School of Gastrointestinal Oncology

Michael A. Choti, MD, discusses the benefit of neoadjuvant chemotherapy in pancreatic cancer.

March 21st 2020, 2:17am

School of Gastrointestinal Oncology

John L. Marshall, MD, discusses the challenges in the colorectal cancer field.

March 14th 2020, 1:33am

PER® New York GU

In metastatic renal cell carcinoma, the use of frontline combination immunotherapy regimens has led to significant survival benefits for patients, and efforts are now being focused on exploring novel options for those who become refractory to this approach.

March 14th 2020, 12:37am

PER® New York GU

Leonard G. Gomella, MD, professor, chair, Department of Urology, and director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the state of genetic testing in prostate cancer.

March 14th 2020, 12:07am

PER® New York GU

Leonard G. Gomella, MD, discusses the state of genetic testing in prostate cancer, shares his recommendations for screening, and provides perspective on where the field is headed.

March 13th 2020, 11:47pm

PER® New York GU

Daniel P. Petrylak, MD, discusses available treatment options in metastatic bladder cancer.

March 13th 2020, 11:33pm

PER® New York GU

In metastatic urothelial cancer, the portfolio of immunologic therapies is robust, but the treatment paradigm for these agents requires refinement.